Prodrug strategies to overcome poor water solubility.

Drug design in recent years has attempted to explore new chemical spaces resulting in more complex, larger molecular weight molecules, often with limited water solubility. To deliver molecules with these properties, pharmaceutical scientists have explored many different techniques. An older but time-tested strategy is the design of bioreversible, more water-soluble derivatives of the problematic molecule, or prodrugs. This review explores the use of prodrugs to effect improved oral and parenteral delivery of poorly water-soluble problematic drugs, using both marketed as well as investigational prodrugs as examples. Prodrug interventions should be considered early in the drug discovery paradigm rather than as a technique of last resort. Their importance is supported by the increasing percentage of approved new drug entities that are, in fact, prodrugs.

[1]  S. Varia,et al.  Phenytoin prodrugs III: water-soluble prodrugs for oral and/or parenteral use. , 1984, Journal of pharmaceutical sciences.

[2]  B. D. Anderson,et al.  Strategies in the design of solution-stable, water-soluble prodrugs I: a physical-organic approach to pro-moiety selection for 21-esters of corticosteroids. , 1985, Journal of pharmaceutical sciences.

[3]  M. Skwarczynski,et al.  ON intramolecular acyl migration reaction in the development of prodrugs and the synthesis of difficult sequence‐containing bioactive peptides , 2004, Biopolymers.

[4]  V. Stella A Case for Prodrugs , 2007 .

[5]  T. Shen,et al.  Chemical and biological studies on indomethacin, sulindac and their analogs. , 1977, Advances in drug research.

[6]  S. Roffler,et al.  Stability of the new prodrug 9-aminocamptothecin glucuronide (9ACG) in the presence of human serum albumin. , 2003, Biochemical pharmacology.

[7]  C. Lipinski Drug-like properties and the causes of poor solubility and poor permeability. , 2000, Journal of pharmacological and toxicological methods.

[8]  Michelle A. Schmidt,et al.  To Market, To Market – 2005 , 2006 .

[9]  J. Fechner,et al.  Pharmacokinetics and clinical pharmacodynamics of the new propofol prodrug GPI 15715 in volunteers. , 2003, Anesthesiology.

[10]  Y. Kiso,et al.  New water-soluble prodrugs of HIV protease inhibitors based on O-->N intramolecular acyl migration. , 2002, Bioorganic & medicinal chemistry.

[11]  G. Amidon,et al.  Design of prodrugs for improved gastrointestinal absorption by intestinal enzyme targeting. , 1985, Methods in enzymology.

[12]  D. Budman,et al.  Pharmacokinetic evaluation of high-dose etoposide phosphate after a 2-hour infusion in patients with solid tumors , 1996, Cancer Chemotherapy and Pharmacology.

[13]  V. J. Stella,et al.  The in Vitro Enzymic Labilities of Chemically Distinct Phosphomonoester Prodrugs , 1992, Pharmaceutical Research.

[14]  J. Melby,et al.  Comparative studies on absorption and metabolic disposal of water-soluble corticosteroid esters. , 1961, Metabolism: clinical and experimental.

[15]  D. Fleisher,et al.  Improved oral drug delivery: solubility limitations overcome by the use of prodrugs , 1996 .

[16]  V. Stella,et al.  A novel prodrug approach for tertiary amines. 2. Physicochemical and in vitro enzymatic evaluation of selected N-phosphonooxymethyl prodrugs. , 1999, Journal of pharmaceutical sciences.

[17]  B. Testa Prodrug research: futile or fertile? , 2004, Biochemical pharmacology.

[18]  T. Wadsten,et al.  Polymorphism of estramustine. , 1989, Journal of pharmaceutical sciences.

[19]  Stella,et al.  Some relationships between the physical properties of various 3-acyloxymethyl prodrugs of phenytoin to structure: potential in vivo performance implications , 1998, Journal of pharmaceutical sciences.

[20]  V. Stella,et al.  Low-melting phenytoin prodrugs as alternative oral delivery modes for phenytoin: a model for other high-melting sparingly water-soluble drugs. , 1983, Journal of pharmaceutical sciences.

[21]  J. Chern,et al.  Design and synthesis of water-soluble glucuronide derivatives of camptothecin for cancer prodrug monotherapy and antibody-directed enzyme prodrug therapy (ADEPT). , 1999, Journal of medicinal chemistry.

[22]  N. Davies,et al.  Clinical Pharmacokinetics of Sulindac , 1997, Clinical pharmacokinetics.

[23]  M. Skwarczynski,et al.  A novel approach of water-soluble paclitaxel prodrug with no auxiliary and no byproduct: design and synthesis of isotaxel. , 2003, Journal of medicinal chemistry.

[24]  Tomoko Ito,et al.  Development of water-soluble prodrugs of the HIV-1 protease inhibitor KNI-727: importance of the conversion time for higher gastrointestinal absorption of prodrugs based on spontaneous chemical cleavage. , 2003, Journal of medicinal chemistry.

[25]  W. Wargin,et al.  Pharmacokinetics of intravenous chloramphenicol sodium succinate in adult patients with normal renal and hepatic function , 1982, Journal of Pharmacokinetics and Biopharmaceutics.

[26]  J. Tack,et al.  In vitro behavior of a phosphate ester prodrug of amprenavir in human intestinal fluids and in the Caco-2 system: illustration of intraluminal supersaturation. , 2007, International journal of pharmaceutics.

[27]  L. Schacter Etoposide phosphate: what, why, where, and how? , 1996, Seminars in oncology.

[28]  C. Conover,et al.  Poly(ethylene glycol) conjugated drugs and prodrugs: a comprehensive review. , 2000, Critical reviews in therapeutic drug carrier systems.

[29]  T. Nevalainen,et al.  Design, synthesis and in vitro evaluation of novel water-soluble prodrugs of buparvaquone. , 2004, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[30]  Qi Gao,et al.  Phosphonooxymethyl prodrugs of the broad spectrum antifungal azole, ravuconazole: synthesis and biological properties. , 2003, Bioorganic & medicinal chemistry letters.

[31]  F. Debon,et al.  Use of steroid anesthesia in surgery. , 1955, Journal of the American Medical Association.

[32]  V. Stella,et al.  Pharmacokinetics of dapsone and amino acid prodrugs of dapsone. , 1994, Drug metabolism and disposition: the biological fate of chemicals.

[33]  V. Stella,et al.  Novel prodrug approach for tertiary amines: synthesis and preliminary evaluation of N-phosphonooxymethyl prodrugs. , 1999, Journal of medicinal chemistry.

[34]  C. V. Pesheck,et al.  Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[35]  B. D. Anderson,et al.  Influence of premicellar and micellar association on the reactivity of methylprednisolone 21-hemiesters in aqueous solution. , 1983, Journal of pharmaceutical sciences.

[36]  R. S. Rogers,et al.  Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). , 1997, Journal of medicinal chemistry.

[37]  M. Butters,et al.  The Discovery and Process Development of a Commercial Route to the Water Soluble Prodrug, Fosfluconazole , 2002 .

[38]  R. Kauffman,et al.  Relative bioavailability of intravenouschloramphenicol succinate and oral chloramphenicol palmitate in infants and children , 1981 .

[39]  D. E. Duggan,et al.  Kinetics of the tissue distributions of sulindac and metabolites. Relevance to sites and rates of bioactivation. , 1980, Drug metabolism and disposition: the biological fate of chemicals.

[40]  J. Iqbal,et al.  Identification of 2-hydroxymethyl-4-[5-(4-methoxyphenyl)-3-trifluoromethyl-pyrazol-1-yl]-N-propionylbenzenesulfonamide sodium as a potential COX-2 inhibitor for oral and parenteral administration. , 2006, Bioorganic & medicinal chemistry.

[41]  V. Stella,et al.  Increased shelf-life of fosphenytoin: solubilization of a degradant, phenytoin, through complexation with (SBE)7m-beta-CD. , 1998, Journal of pharmaceutical sciences.

[42]  Gordon L Amidon,et al.  A Mechanistic Approach to Understanding the Factors Affecting Drug Absorption: A Review of Fundamentals , 2002, Journal of clinical pharmacology.

[43]  Keith Tan,et al.  The effects of hepatic impairment on the pharmacokinetics of fosfluconazole and fluconazole following a single intravenous bolus injection of fosfluconazole. , 2004, British journal of clinical pharmacology.

[44]  J. Fechner,et al.  Pharmacokinetics and pharmacodynamics of the new propofol prodrug GPI 15715 in rats , 2003, European journal of anaesthesiology.

[45]  V. Stella,et al.  Preparation, characterization and in vivo conversion of new water-soluble sulfenamide prodrugs of carbamazepine. , 2007, Bioorganic & medicinal chemistry letters.

[46]  J. Supko,et al.  Dose-dependent pharmacokinetics of rapamycin-28-N,N-dimethylglycinate in the mouse , 2004, Cancer Chemotherapy and Pharmacology.

[47]  R. Guthrie,et al.  Safety, Tolerance and Pharmacokinetics of Intravenous Doses of the Phosphate Ester of 3‐Hydroxymethyl‐5,5‐Diphenylhydantoin: A New Prodrug of Phenytoin , 1988, Journal of clinical pharmacology.

[48]  K. C. Murdock,et al.  N-phosphoryl derivatives of bisantrene. Antitumor prodrugs with enhanced solubility and reduced potential for toxicity. , 1993, Journal of medicinal chemistry.

[49]  Valentino J. Stella,et al.  Prodrugs : challenges and rewards , 2007 .

[50]  Bernard Testa,et al.  Hydrolysis in drug and prodrug metabolism : chemistry, biochemistry, and enzymology , 2003 .

[51]  J. Kovach,et al.  Disposition of bisantrene in humans and rabbits: evidence for intravascular deposition of drug as a cause of phlebitis. , 1983, Cancer research.

[52]  Ronald T. Borchardt,et al.  Pharmaceutical profiling in drug discovery for lead selection , 2004 .

[53]  E. Furfine,et al.  Preclinical Pharmacology and Pharmacokinetics of GW433908, a Water-Soluble Prodrug of the Human Immunodeficiency Virus Protease Inhibitor Amprenavir , 2004, Antimicrobial Agents and Chemotherapy.

[54]  Patrick Augustijns,et al.  Characterization of fasted‐state human intestinal fluids collected from duodenum and jejunum , 2006, The Journal of pharmacy and pharmacology.

[55]  B. D. Anderson,et al.  Strategies in the design of solution-stable, water-soluble prodrugs III: influence of the pro-moiety on the bioconversion of 21-esters of corticosteroids. , 1985, Journal of pharmaceutical sciences.

[56]  Pharmacokinetics and pharmacodynamics of the new propofol prodrug GPI 15715 in rats: Retraction , 2003 .

[57]  R. Borchardt Optimizing the "drug-like" properties of leads in drug discovery , 2006 .

[58]  G. Amidon,et al.  Oral absorption of 21-corticosteroid esters: a function of aqueous stability and intestinal enzyme activity and distribution. , 1986, Journal of pharmaceutical sciences.

[59]  Bernard,et al.  Advances in Drug Research , 1964 .

[60]  A. Klein-Szanto,et al.  CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. , 2003, Cancer research.

[61]  V. Stella,et al.  Degradation pathways of a peptide boronic acid derivative, 2-Pyz-(CO)-Phe-Leu-B(OH)(2). , 2000, Journal of pharmaceutical sciences.

[62]  C. Perry,et al.  Estramustine Phosphate Sodium , 1995, Drugs & aging.

[63]  S. Becker,et al.  Fosamprenavir: advancing HIV protease inhibitor treatment options , 2004, Expert Opinion on Pharmacotherapy.

[64]  J. Dressman,et al.  Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. , 1997, Advanced drug delivery reviews.

[65]  C. Koboldt,et al.  N-[[(5-methyl-3-phenylisoxazol-4-yl)-phenyl]sulfonyl]propanamide, sodium salt, parecoxib sodium: A potent and selective inhibitor of COX-2 for parenteral administration. , 2000, Journal of medicinal chemistry.

[66]  J. Singer,et al.  Synthesis and in Vivo Antitumor Activity of Poly(l-glutamic acid) Conjugates of 20(S)-Camptothecin , 2003 .

[67]  J. Fischer,et al.  Fosphenytoin: clinical pharmacokinetics and comparative advantages in the acute treatment of seizures. , 2003, Clinical pharmacokinetics.

[68]  V. Stella,et al.  Amino acid derivatives of dapsone as water-soluble prodrugs , 1995 .

[69]  Thomas J. Raub,et al.  P-glycoprotein recognition of substrates and circumvention through rational drug design. , 2006, Molecular pharmaceutics.

[70]  R. Schowen,et al.  A Mechanistic and Kinetic Study of the E-Ring Hydrolysis and Lactonization of a Novel Phosphoryloxymethyl Prodrug of Camptothecin , 2003, Pharmaceutical Research.

[71]  V. Stella Prodrugs as therapeutics , 2004 .

[72]  E. Falch,et al.  Allopurinol prodrugs. V. Water-soluble N-substituted (aminomethyl)benzoyloxymethyl allopurinol derivatives for parenteral or rectal delivery , 1990 .

[73]  W. Plunkett,et al.  Metabolism and action of fludarabine phosphate. , 1990, Seminars in oncology.

[74]  B. Testa,et al.  Lessons learned from marketed and investigational prodrugs. , 2004, Journal of medicinal chemistry.

[75]  O. H. Chan,et al.  Evaluation of a Targeted Prodrug Strategy to Enhance Oral Absorption of Poorly Water-Soluble Compounds , 1998, Pharmaceutical Research.

[76]  V. Stella,et al.  Prodrugs and Parenteral Drug Delivery , 2007 .

[77]  S. Varia,et al.  Phenytoin prodrugs IV: Hydrolysis of various 3-(hydroxymethyl)phenytoin esters. , 1984, Journal of pharmaceutical sciences.

[78]  C. Jeleazcov,et al.  Sedation with GPI 15715, a water-soluble prodrug of propofol, using target-controlled infusion in volunteers. , 2005, Anesthesia and analgesia.

[79]  V. Stella A case for prodrugs: Fosphenytoin , 1996 .

[80]  B. D. Anderson,et al.  Strategies in the design of solution-stable, water-soluble prodrugs II: properties of micellar prodrugs of methylprednisolone. , 1985, Journal of pharmaceutical sciences.

[81]  J. Gray,et al.  The parenteral toxicity of clindamycin 2-phosphate in laboratory animals. , 1974, Toxicology and applied pharmacology.

[82]  Christos Reppas,et al.  Biorelevant Dissolution Testing to Predict the Plasma Profile of Lipophilic Drugs After Oral Administration , 2001, Pharmaceutical Research.

[83]  M. Percival,et al.  The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor. , 1999, Bioorganic & medicinal chemistry letters.

[84]  T. Fujiwara,et al.  Development of Anti-Influenza Virus Drugs I: Improvement of Oral Absorption and In Vivo Anti-Influenza Activity of Stachyflin and Its Derivatives , 1999, Pharmaceutical Research.

[85]  H. Möllmann,et al.  Kinetics of methylprednisolone and its hemisuccinate ester , 1985, Clinical pharmacology and therapeutics.

[86]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[87]  G. Flynn,et al.  Absorption Rate Limit Considerations for Oral Phosphate Prodrugs , 2003, Pharmaceutical Research.

[88]  C. Larsen,et al.  Prodrugs as drug delivery systems. XXVI: Preparation and enzymatic hydrolysis of various water-soluble amino acid esters of metronidazole , 1984 .

[89]  W. Prince,et al.  Pharmacokinetics of GW433908, a Prodrug of Amprenavir, in Healthy Male Volunteers , 2002, Journal of clinical pharmacology.

[90]  R. Fanelli,et al.  Analytical and pharmacokinetic studies on the optic isomers of oxazepam succinate half-ester. , 1972, Biochemical pharmacology.

[91]  M. Salmona,et al.  In vitro hydrolysis of oxazepam succinate half-ester by a stereospecific soluble esterase from different animal species. , 1974, Journal of pharmaceutical sciences.

[92]  M. Shelton,et al.  Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug. , 2006, Clinical pharmacokinetics.

[93]  Y. Kiso,et al.  Effect of the acyl groups on O-->N acyl migration in the water-soluble prodrugs of HIV-1 protease inhibitor. , 2003, Bioorganic & medicinal chemistry letters.

[94]  J. Therrien,et al.  A prodrug approach toward the development of water soluble fluoroquinolones and structure--activity relationships of quinoline-3-carboxylic acids. , 2004, Journal of medicinal chemistry.

[95]  V. Stella,et al.  Hydrolysis of pharmaceutically relevant phosphate monoester monoanions: correlation to an established structure-reactivity relationship. , 1993, Journal of pharmaceutical sciences.

[96]  Richard B Greenwald,et al.  Effective drug delivery by PEGylated drug conjugates. , 2003, Advanced drug delivery reviews.

[97]  J. Leppänen,et al.  Synthesis of a water-soluble prodrug of entacapone. , 2000, Bioorganic & medicinal chemistry letters.

[98]  AQUAVAN injection, a water-soluble prodrug of propofol, as a bolus injection: a phase I dose-escalation comparison with DIPRIVAN (part 1): pharmacokinetics. , 2005, Anesthesiology.

[99]  R. Corradino,et al.  ABSORPTION, METABOLISM, AND EXCRETION OF OXAZEPAM AND ITS SUCCINATE HALF-ESTER. , 1964, Journal of pharmaceutical sciences.

[100]  R. Moss,et al.  Propofol Phosphate, a Water-Soluble Propofol Prodrug:In Vivo Evaluation , 2002, Anesthesia and analgesia.

[101]  Terry R Stouch,et al.  Progress in understanding the structure-activity relationships of P-glycoprotein. , 2002, Advanced drug delivery reviews.

[102]  Tycho Heimbach,et al.  Overcoming Poor Aqueous Solubility of Drugs for Oral Delivery , 2007 .

[103]  F. Abramson,et al.  Bioavailability, distribution and pharmacokinetics of diethystilbestrol produced from stilphostrol. , 1982, The Journal of urology.

[104]  Y. Rojanasakul,et al.  Experimental and Computational Studies of Epithelial Transport of Mefenamic Acid Ester Prodrugs , 2005, Pharmaceutical Research.

[105]  S. Varia,et al.  Phenytoin prodrugs V: In vivo evaluation of some water-soluble phenytoin prodrugs in dogs. , 1984, Journal of pharmaceutical sciences.

[106]  V. Stella,et al.  Aqueous solubility and dissolution rate does not adequately predict in vivo performance: a probe utilizing some N-acyloxymethyl phenytoin prodrugs. , 1999, Journal of pharmaceutical sciences.

[107]  S. Varia,et al.  Phenytoin prodrugs VI: In vivo evaluation of a phosphate ester prodrug of phenytoin after parenteral administration to rats. , 1984, Journal of pharmaceutical sciences.

[108]  R. Scott,et al.  The Entropy of Solution of Nonelectrolytes , 1952 .

[109]  B. Ruggeri,et al.  A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clini , 2003, Journal of medicinal chemistry.

[110]  H. Möllmann,et al.  Comparative Pharmacokinetics of Methylprednisolone Phosphate and Hemisuccinate in High Doses , 1988, Pharmaceutical Research.

[111]  Sevtap Arikan,et al.  Ravuconazole Eisai/Bristol-Myers Squibb. , 2002, Current opinion in investigational drugs.

[112]  F. Schabel,et al.  Biologic activity of 9-β-d-arabinofuranosyl-2-fluoroadenine, a metabolically stable analog of 9-β-d-arabinofuranosyladenine , 1977 .

[113]  L. Sorbera,et al.  Valdecoxib and Parecoxib Sodium , 2001 .

[114]  A. Burstein,et al.  Phenytoin pharmacokinetics following oral administration of phenytoin suspension and fosphenytoin solution to rats , 1999, Epilepsy Research.

[115]  Michael J. Hageman,et al.  Solubility, Solubilization and Dissolution in Drug Delivery During Lead Optimization , 2006 .